Ilias W, Jansen M
Barmherzige Brüder Hospital, Vienna, Austria.
Br J Clin Pract. 1996 Jun;50(4):197-202.
This 24-hour, randomised, double-blind, placebo-controlled study compared the efficacy and tolerability of intravenous injections of lornoxicam 4 mg and 8 mg with tramadol 50 mg in 78 female patients aged 20-65 years with moderate to intolerable postoperative pain following mainly hysterectomy. Patients who received lornoxicam 8 mg had a significantly (p < 0.05) longer time to first remedication than placebo recipients and tended to have a greater reduction in pain intensity and a longer time to withdrawal due to "non-response' than tramadol and placebo patients. Lornoxicam was well tolerated at both doses and was associated with a lower incidence of adverse events than tramadol. Thus, intravenous lornoxicam at a dose of 8 mg is superior to placebo and at least as effective as intravenous tramadol 50 mg in relieving moderate to intolerable post-hysterectomy pain. Furthermore, lornoxicam seems to possess a more favourable tolerability profile than tramadol.
这项为期24小时的随机、双盲、安慰剂对照研究，比较了4毫克和8毫克氯诺昔康静脉注射与50毫克曲马多对78名年龄在20至65岁、主要因子宫切除术后有中度至难以忍受疼痛的女性患者的疗效和耐受性。接受8毫克氯诺昔康的患者首次用药的时间比接受安慰剂的患者显著更长（p < 0.05），并且与曲马多和安慰剂组患者相比，疼痛强度降低幅度更大，因“无反应”而停药的时间更长。两种剂量的氯诺昔康耐受性良好，且与曲马多相比不良事件发生率更低。因此，8毫克剂量的静脉注射氯诺昔康在缓解子宫切除术后中度至难以忍受的疼痛方面优于安慰剂，且至少与50毫克静脉注射曲马多一样有效。此外，氯诺昔康似乎比曲马多具有更良好的耐受性。
